{"public_id":"co_174c51fbb203a98e09edf479567bf84c","status":"active","merged_into_public_id":null,"resolved_public_id":"co_174c51fbb203a98e09edf479567bf84c","name":"peripheral neuropathy","description":"Nerve damage causing numbness or pain in the extremities, monitored as an adverse event given the proteasome inhibitor drug class.","aliases":[],"types":["adverse event"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":205099724,"title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","citation_count":960,"url":"https://sah.borca.ai/papers/205099724"}],"claims":[{"public_id":"cl_2017a7ba0d0509b9c61c33ae5603498c","text":"Thrombocytopenia, rash, and peripheral neuropathy occurred more frequently in the ixazomib group than in the placebo group (grade 3/4 thrombocytopenia, 12%/7% vs. 5%/4%; rash, 36% vs. 23%; peripheral neuropathy, 27% vs. 22%).","corpus_id":205099724,"url":"https://sah.borca.ai/claims/cl_2017a7ba0d0509b9c61c33ae5603498c"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_174c51fbb203a98e09edf479567bf84c","url":"https://sah.borca.ai/concepts/co_174c51fbb203a98e09edf479567bf84c"}